Search

Dr. Tagore is a postdoctoral fellow in the Cancer Biology and Genetics Program at the Sloan Kettering Institute studying cell communication in cancer.

… Monday, June 8, 2020 Summary Mohita Tagore is a postdoctoral fellow in the Cancer Biology and Genetics Program at the Sloan Kettering Institute. She is a 2020 winner of a Kravis WISE postdoctoral fellowship and will be presenting her research at the inaugural Kravis WiSE Symposium on July 8, 2020. In

After immunotherapy and targeted therapy failed to bring a patient's melanoma under control, MSK doctors offered her a new treatment called tumor-infiltrating lymphocyte, or TIL, therapy.

… Tuesday, October 28, 2025 It was not the news that Pattie Fuller wanted to hear.  Doctors at a local hospital in upstate New York told her that despite surgery and several rounds of  immunotherapy , her  melanoma was growing. The melanoma ultimately grew to be stage 4. It spread from her scalp to the

Memorial Sloan Kettering Cancer Center (MSK) announces its most recent awards and appointments for the institution’s physicians, scientists, nurses, and staff.

… Wednesday, September 15, 2021 Memorial Sloan Kettering Cancer Center (MSK) announces the following awards and appointments: MSK Receives National Cancer Institute (NCI) Specialized Programs of Research Excellence (SPORE) Grant Omar Abdel-Wahab and Martin Tallman The National Cancer Institute (NCI) awarded

Despite significant advances in supportive care and improvements in allogeneic hematopoietic stem cell transplantationoutcomes, about one in every three patients succumbs to post-transplant toxicities, half of which are not related to graft-versus-host disease.

… Thursday, March 15, 2018 Despite significant advances in supportive care and improvements in allogeneic hematopoietic stem cell transplantation outcomes, about one in every three patients succumbs to post-transplant toxicities, half of which are not related to graft-versus-host disease (GVHD). While

Investigators found that olaparib extended progression-free survival by an average of three months in women with advanced breast cancer.

… Sunday, June 4, 2017 Summary A new trial of olaparib found that the drug extended progression-free survival by an average of three months in women with advanced breast cancer . Olaparib is in a class of drugs called PARP inhibitors. Update: On January 12, 2018 the FDA approved olaparib (Lynparza®) for

The US Food and Drug Administration (FDA) has announced that it has approved the drug vemurafenib for the treatment of patients with BRAF V600-mutant Erdheim-Chester disease (ECD). This is the first approval of a targeted therapy based on a basket study and the first-ever drug approved for ECD, a rare blood disorder. This landmark approval came as a direct result of research at Memorial Sloan Kettering Cancer Center (MSK).

… Monday, November 6, 2017 Bottom Line The US Food and Drug Administration (FDA) has announced that it has approved the drug vemurafenib for the treatment of patients with BRAF V600 -mutant Erdheim-Chester disease (ECD). This is the first approval of a targeted therapy based on a basket study and the first-ever

Steve Glass brings more than three decades of experience across the healthcare provider and payer sectors and will oversee MSK’s financial strategy and operations.

… Thursday, March 19, 2026 Memorial Sloan Kettering Cancer Center (MSK) today announced the appointment of Steve Glass as Executive Vice President and Chief Financial Officer effective immediately. Glass brings more than three decades of experience across the healthcare provider and payer sectors and will

Memorial Sloan Kettering Cancer Center (MSK), The Rockefeller University, and Weill Cornell Medicine today announced that the Tri-Institutional Therapeutics Discovery Institute, Inc. (Tri-I TDI) has renewed its collaborations with partners Takeda Pharmaceutical Company Limited (Takeda) and Bridge Medicines.

… Tuesday, February 25, 2020 Memorial Sloan Kettering Cancer Center (MSK), The Rockefeller University, and Weill Cornell Medicine today announced that the Tri-Institutional Therapeutics Discovery Institute, Inc. (Tri-I TDI) has renewed its collaborations with partners Takeda Pharmaceutical Company Limited

ATLANTA, June 4, 2006 - According to a new study, the drug sunitinib malate (Sutent®) is more effective than the current standard cytokine treatment given as an initial therapy for patients with advanced kidney cancer, also known as metastatic renal cell carcinoma (mRCC). The study is being presented today at the annual American Society of Clinical Oncology meeting.

… Sunday, June 4, 2006 According to a new study, the drug sunitinib malate (Sutent®) is more effective than the current standard cytokine treatment given as an initial therapy for patients with advanced kidney cancer , also known as metastatic renal cell carcinoma (mRCC). The study is being presented today

Lung cancer co-opts genes that normally help a fetus develop and evade the mother’s immune system — leading to poorer outcomes in female patients, an MSK research team has found.

… Monday, April 28, 2025 Lung cancer can co-opt genes that normally help a fetus develop and evade the mother’s immune system. And while these pregnancy-specific glycoproteins (PSGs) can get activated in the cancers of both men and women, female patients had poorer outcomes, a Memorial Sloan Kettering